Clinical Trial Update: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) [Phase 3]

View source ↗

Summary

Phase 3 trial update for subcutaneous CT-P13 (infliximab) in moderately to severely active ulcerative colitis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• CT-P13 (infliximab) (infliximab)

Snippet

Sponsor: Celltrion | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2023-09-28